Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
133
resultados
Última actualización
09/03/2025 [06:54:00]
Resumen de: WO2025046158A1
The invention relates to a method for controlling glucose in a flexible-structure bihormonal artificial pancreas that manages optional meal and/or exercise alerts by means of coordinated control actions, comprising: measuring a plasma glucose signal; calculating an incremental plasma glucose measurement (y); defining a model for incremental plasma glucose; defining a carbohydrate ingestion as dependent on a carbohydrate content estimated by the patient; defining an expected postprandial incremental plasma glucose y*(s) according to an insulin bolus that has been administered; defining a corrected incremental plasma glucose y̅(s), a corrected insulin infusion ū(s) and a corrected carbohydrate ingestion d̅(s); defining a virtual control action μ(s), divided between regulatory actions μ r and counterregulatory actions μ cr ; and calculating the control actions using a 2-DOF feedback controller with a prefilter having a nominal value F r (s).
Resumen de: WO2025044331A1
Disclosed in the present invention is a closed-loop artificial pancreas system for safe infusion. During long-time missing of real-time blood glucose value data, on the basis of historical blood glucose values and blood glucose values of fingertips, the closed-loop artificial pancreas system can continue to calculate the infusion amount of insulin required by a patient and infuse a proper amount of insulin into the patient, and will not infuse an improper amount of insulin due to missing of real-time blood glucose value data and even interrupt the infusion of insulin, avoiding the life risk of the patient, and facilitating treatment of the patient.
Resumen de: AU2025201073A1
This document discusses, among other things, systems and methods to compensate for the effects of temperature on sensors, such as analyte sensor. An example method may include determining a temperature-compensated glucose concentration level by receiving a temperature signal indicative of a temperature parameter of an external component, receiving a glucose signal indicative of an in vivo glucose concentration level, and determining a compensated glucose concentration level based on the glucose signal, the temperature signal, and a delay parameter.
Resumen de: AU2023333103A1
Exemplary embodiments may apply a transform or filter to analyte level values of the users to make the analyte level values conform with a normal distribution that is symmetric relative to the mean. The transformed or filtered analyte level values may be used by the control system of a medicament delivery device in determining medicament delivery doses. In some embodiments, the medicament is insulin, and the analyte level is a glucose level of a user. In such instances, a logarithmic filter or transform may be applied to the glucose level readings of the user.
Resumen de: WO2025048045A1
The present invention relates to a sensor strip storage-type device for measuring urine glucose levels and vascular elasticity, wherein the sensor strip storage-type device is capable of measuring urine glucose levels in a non-invasive manner, quantitatively measuring glucose levels through a digitized sensor, being capable of being conveniently carried by means of sealing and storing a plurality of sensor strips that can be used multiple times, and measuring vascular elasticity during use.
Resumen de: US2025072774A1
The present disclosure relates to noninvasive methods, devices, and systems for measuring various blood constituents or analytes, such as glucose. In an embodiment, a light source comprises LEDs and super-luminescent LEDs. The light source emits light at at least wavelengths of about 1610 nm, about 1640 nm, and about 1665 nm. In an embodiment, the detector comprises a plurality of photodetectors arranged in a special geometry comprising one of a substantially linear substantially equal spaced geometry, a substantially linear substantially non-equal spaced geometry, and a substantially grid geometry.
Resumen de: US2025072792A1
The present invention discloses a system and method for managing blood glucose level. The system comprises a computing device in communication with a continuous glucose monitoring (CGM) device attached to a user and a wearable device configured to be worn by the user. The computing device is configured to receive the blood glucose level of the user from the continuous glucose monitoring device, or its associated app. The computing device is further configured to enable the user to set one or more predetermined ranges of blood glucose level and set an alert for each predefined range. The computing device is further configured to determine whether the blood glucose level is within one or more predetermined ranges. The computing device is further configured to determine at least one alert corresponding to the blood glucose level and enable the wearable device to provide the determined alert until the user disables the alert.
Resumen de: US2025073386A1
A device for delivering insulin to a user, the device configured as a wearable apparatus or system in which continuous glucose monitoring (CGM), insulin delivery and control functionality are provided to ensure insulin is delivered to the user, the device comprising: a reservoir for storing insulin; a catheter configured to deliver insulin to a subcutaneous layer of the user; an introducer needle movable with respect to the catheter, the introducer needle configured to facilitate (a) insertion of the catheter into the subcutaneous layer of the user and (b) removal of the introducer needle to enable delivery of insulin through the catheter; a micropump, in fluid communication with the reservoir and catheter, for pumping insulin from the reservoir through the catheter; and a pressure sensor separate from and in fluid communication with an outlet port of the micropump, the sensor comprising: a first wafer defining an inlet port, and outlet port and fluid channel communicating with the inlet and outlet ports; a second wafer covering the fluid channel and including a pressure sensing mechanism; and a piezoelectric device layered on the first wafer and configured to generate a signal in response to the pressure sensing mechanism that is representative of pressure within channel.
Resumen de: US2025073440A1
A transport element for transporting a substance in a reservoir includes a transport means, such as a conduit, tube, hose or the like, and a connector arranged at an inlet end of the transport means for connecting to the reservoir such that in a connected condition in which the connector is connected to said reservoir a medium through flow connection is provided between said reservoir and the inlet end of the transport means for receiving said substance from said reservoir. The connector includes aligning and holding means for aligning and holding the reservoir in a predetermined orientation with respect to and/or position along a longitudinal axis of the connector. An infusion set, system or combination including transport element, and a method of at least fluidly connecting such a transport element to a reservoir.
Resumen de: WO2025050007A1
The present disclosure describes lactate-responsive sensors, sensing systems incorporating a lactate-responsive sensor, and methods of use thereof that would be beneficial for continuously monitoring lactate levels and determining lactate thresholds (both aerobic and anaerobic thresholds). The present disclosure also relates to an analyte sensor for continuously detecting glucose and lactate levels.
Resumen de: US2025079008A1
Disclosed herein are system, method, and computer program product embodiments for improving detection and treatment of patient conditions based on continuous analyte data. The disclosed techniques utilize analyte data, such as lactate, glucose, and creatinine, provided from a continuous analyte sensor to predict patient outcomes. The prediction may also take into account other medical information associated with the patient, such as patient vital signs and medical history. The disclosed system allows for early and non-invasive prediction of patient outcomes in various settings including a hospital setting, a home setting, disease (e.g., heart failure, sepsis) detection, and high risk surgery monitoring. The disclosed system also is configured to monitor patient conditions and generating alerts and/or notifications based on the predicted patient outcomes to provide preemptive treatment of patient conditions.
Resumen de: US2025072793A1
Embodiments relate to a system for processing glucose data by efficient glucose database management. The system includes a physical data store containing glucose measurement data and a representation for at least one cluster of the glucose measurement data, wherein the representation approximates a glycemic profile vector array for a cluster of multiple glucose profiles segmented by plural time ranges. The system includes a processor and computer memory configured with instructions stored thereon that when executed will cause the processor to: 1) receive glucose measurements; 2) convert the glucose measurements into vectorial form; 3) search the physical data store by comparing a newly received glucose measurement to a centroid of a cluster using a similarity metric; 3) classify the newly received glucose measurement with a cluster having a matched similarity metric based on the comparing; and 4) ascribe a treatment to the newly received glucose measurement.
Resumen de: WO2023211879A1
Disclosed herein are apparatuses and methods that can simplify delivery of meal boluses in diabetes therapy. Rather than requiring a user to enter a number of carbohydrates for a given meal, the system can automatically provide a predetermined amount of insulin when the user indicates that a meal is going to be consumed. Providing such predetermined, fixed meal boluses provides a lower cognitive burden alternative for the mealtime experience.
Resumen de: WO2023212738A1
Disclosed is a meal detection and meal size estimation machine learning technology. In some embodiments, the techniques entail applying to a trained multioutput neural network model a set of input features, the set of input features representing glucoregulatory management data, insulin on board, and time of day, the trained multioutput neural network model representing multiple fully connected layers and an output layer formed from first and second branches, the first branch providing a meal detection output and the second branch providing a carbohydrate estimation output; receiving from the meal detection output a meal detection indication; and receiving from the carbohydrate estimation output a meal size estimation.
Resumen de: US2025070458A1
A glucose monitoring device is provided. The glucose monitoring device includes a housing having a first portion and a second portion, the second portion operable to be placed adjacent to a human body during operation of the glucose monitoring device. The glucose monitoring device further includes a circuit board positioned between the first portion and the second portion of the housing, the circuit board having a trace antenna. The glucose monitoring device further includes a conductive structure spaced apart from the circuit board.
Resumen de: US2025064359A1
Disclosed are devices, systems and methods for in vivo monitoring of localized environment conditions within a patient user by measuring analytes, including glucose, oxygen, and/or other analytes. In some aspects, a sensor device includes a wafer-based substrate, at least one electrochemical sensor two-electrode contingent including a working electrode and a reference electrode on the substrate and configured to detect a target analyte in a body fluid when the sensor device is deployed within a subject's body, where the working electrode is functionalized by a chemical layer configured to facilitate a reaction involving the target analyte that produces an electrical signal; and an electronics unit in communication with the electrochemical sensor electrode contingent to transmit the electrical signal to an external processor.
Resumen de: US2025064361A1
An analyte sensor for use in medical devices for measuring analyte data in an analyte carrying fluid, in particular for measuring glucose data, which includes: a first electrode being a working electrode, a second electrode, a substrate carrying the first electrode and the second electrode, at least one membrane which at least partially covers the first electrode, wherein the at least one membrane comprises a membrane material that is impermeable to the analyte carrying fluid and/or the analyte, wherein the at least one membrane comprises at least one opening, and wherein the at least one membrane is configured for controlling the flux of the analyte carrying fluid and/or the analyte to the first electrode via the at least one opening. Methods of operation, a continuous analyte monitoring system and a kit with such a sensor are also disclosed.
Resumen de: US2025064362A1
An embodiment may provide a method for calibrating sensitivity for glucose measurement including: obtaining an offset value for determining sensitivity; determining a first sensitivity from a sensor data and a reference glucose value, based on the offset value; and determining sensitivity by adjusting the first sensitivity, wherein the determining of the sensitivity includes obtaining one sensitivity, and determining sensitivity A by adjusting the one sensitivity by reflecting an average sensor data obtained by averaging a plurality of sensor data and an average glucose value obtained by averaging a plurality of glucose values to the one sensitivity; and determining the sensitivity A as the sensitivity.
Resumen de: US2025064327A1
The present invention discloses a biosensor system designed for non-invasive measurement and prediction of blood glucose and blood pressure levels. The system comprises a biosensor module, a processing module, a convolutional neural network (CNN) module, a display module, a user interface module, and a control module. The biosensor module incorporates optical spectroscopic techniques to capture physiological signals, which are preprocessed to eliminate noise and optimize for subsequent analysis. A scalogram image is generated from the preprocessed signals, and the processing module further processes the image. The CNN module utilizes the processed scalogram image to accurately measure and predict blood glucose and blood pressure levels. The system offers a user-friendly interface displayed on a screen, enabling users to interact and view the predicted results. The proposed method is non-invasive, relying on capturing and analyzing the physiological signals to provide reliable and convenient monitoring of blood glucose and blood pressure levels.
Resumen de: US2025064351A1
An embodiment may provide a method for calibrating sensitivity for glucose measurement including: obtaining an offset value for determining sensitivity; determining a first sensitivity from a sensor data and a reference glucose value, based on the offset value; and determining sensitivity by adjusting the first sensitivity, wherein the determining of the sensitivity includes obtaining the first sensitivity, and determining sensitivity A by adjusting the first sensitivity according to an elapsed period of time after a sensor is inserted into a body; obtaining the first sensitivity, and determining sensitivity B by adjusting the first sensitivity by reflecting an average sensor data obtained by averaging a plurality of sensor data and an average glucose value obtained by averaging a plurality of glucose values to the first sensitivity; and determining any one of the sensitivity A and the sensitivity B as the sensitivity.
Resumen de: US2025064350A1
A continuous glucose monitor, comprising a housing and a circuit board arranged in the housing, wherein an electronic component is carried on the circuit board; a probe assembly configured to penetrate skin and connected to the circuit board; and an auxiliary sensor connected to the circuit board and configured to detect a compressed state of the continuous glucose monitor. The continuous glucose monitor provided in the present disclosure can identify its own compressed state, thereby improving the accuracy of glucose measurement.
Resumen de: US2025064632A1
A fingertip warming device that can be used on either hand, will aid in warming of fingertips to help increase blood flow to the fingertips of the user for the purpose of easing the process of drawing blood, which will be used to check the user's glucose levels. The device will have warming elements either embedded in the distal end of fingertip slots/compartments or allow for the use of a heatable insert that will also reside in the distal end of the device for the purpose of warming the user's fingertips. The device will provide either flaps or a hole through which the user's fingertips can be exposed to allow for collection of a blood sample for testing glucose levels.
Resumen de: US2025065039A1
The disclosed embodiments are directed to a wearable automatic drug delivery device configured to provide basal-only dosing of insulin. In a primary embodiment, the wearable drug delivery device is configured to provide automatic operation and provides audible alerts and visual status indicators to the patient. In other embodiments, the patient may have some degree of control over the operation of the device by providing tapping gestures on housing of the device. In yet another embodiment, the patient may provide input and receive status from the device via an application executing on a portable computing device in wireless communication with the wearable drug delivery device.
Resumen de: US2025064353A1
A blood glucose measuring apparatus and a method of operating the blood glucose measuring apparatus are provided. The blood glucose measuring method includes extracting a measurement signal based on signals captured by a cell capsule comprising a reservoir configured to accommodate cells, including distinguishing the signals from noise; and estimating a characteristic of the cells based on the extracted measurement signal. The signals have respective oscillations that are dependent on a membrane action potential bursts phase and a membrane lower potential inter-burst phase of the cells.
Nº publicación: US2025064328A1 27/02/2025
Solicitante:
WILLOW LABORATORIES INC [US]
Willow Laboratories, Inc
Resumen de: US2025064328A1
The present disclosure includes a handheld processing device including medical applications for minimally and noninvasive glucose measurements. In an embodiment, the device creates a patient specific calibration using a measurement protocol of minimally invasive measurements and noninvasive measurements, eventually creating a patient specific noninvasive glucometer. Additionally, embodiments of the present disclosure provide for the processing device to execute medical applications and non-medical applications.
BOPI
Sede Electrónica
